Huadong Medicine

Chongqing Yuyan is a biomedical innovation and medical beauty product research and development company. It intends to address the biosafety concerns associated with extracting natural botulinum toxin from the host Clostridium botulinum.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany, that specializes in oncology, focusing on the development of antibody drug conjugates (ADCs) using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. The company is advancing several therapeutic candidates, including HDP-101 for multiple myeloma, PSMA for prostate cancer, and CDXX for Non-Hodgkin lymphoma and other tumors. Heidelberg Pharma is also engaged in the development of MGTA-XX-ATACs for hematopoietic stem cells and conditioning programs for blood cancers and genetic diseases. In addition to its therapeutic development, the company provides preclinical research services in oncology, as well as inflammatory and autoimmune diseases, offering expertise in pharmacology, drug metabolism, and molecular biology. Established in 1997 and formerly known as Wilex AG, Heidelberg Pharma AG has evolved into a significant player in the biopharmaceutical sector.

Founded in 2015, Ashvattha Therapeutics develops precision therapeutics targeting actively endocytosing cells. Its pipeline focuses on neurology, oncology, and ophthalmology, aiming to treat diseases with improved efficacy and reduced side effects.

R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

R2 Technologies focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers.

Ningbo Donghai Bank offers services for business banking. They collaborate with the corporate culture of implementing sunshine management, forming a sunshine team and business, offering a sunshine service, and creating a sunny brand. They aim to create a business with qualities, values, and compassion a regional bank an enhanced service provider; to make appropriate contributions to the high-quality development of the regional economy and society, and to continuously embark on new endeavors.